Proteomedix AG
Wagistrasse 23
8952 Schlieren


The PSA test is usually based on the early detection of prostate cancer. If the PSA value is too high, take a tissue sample from the prostate. This intervention is unpleasant – and not necessary for the majority of men. In three out of four cases the cancer suspicion proves to be wrong. The PSA test is therefore even controversial among physicians. ProteoMediX wants to put a test on the market, which reduces the high rate of misdiagnosis and thus unnecessary biopsies. In a first study, the hit rate of the new test was 80 percent. The study, which was published in the prestigious American scientific journal PNAS, caused a great deal of attention to specialists.

Other team members

Christian Brühlmann